These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 11838623

  • 1. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.
    Dannon PN, Iancu I, Grunhaus L.
    Hum Psychopharmacol; 2002 Oct; 17(7):329-33. PubMed ID: 12415550
    [Abstract] [Full Text] [Related]

  • 3. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [Abstract] [Full Text] [Related]

  • 4. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH, Goa KL.
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF.
    J Clin Psychiatry; 2000 Aug; 61 Suppl 10():31-8. PubMed ID: 10910015
    [Abstract] [Full Text] [Related]

  • 6. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J.
    J Clin Psychiatry; 1998 Aug; 59 Suppl 14():8-10. PubMed ID: 9818624
    [Abstract] [Full Text] [Related]

  • 7. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
    Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP.
    Am J Psychiatry; 1998 Jan; 155(1):36-42. PubMed ID: 9433336
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
    Versiani M, Amin M, Chouinard G.
    J Clin Psychopharmacol; 2000 Feb; 20(1):28-34. PubMed ID: 10653205
    [Abstract] [Full Text] [Related]

  • 10. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.
    Depress Anxiety; 2007 Feb; 24(1):1-14. PubMed ID: 16894619
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H, Van Moffaert M, Gagiano CA.
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [Abstract] [Full Text] [Related]

  • 12. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC, Portera L, Leon AC.
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [Abstract] [Full Text] [Related]

  • 13. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A.
    Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
    [Abstract] [Full Text] [Related]

  • 14. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ.
    Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.
    Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L.
    Pharmacopsychiatry; 2004 Sep; 37(5):206-10. PubMed ID: 15359375
    [Abstract] [Full Text] [Related]

  • 16. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [Abstract] [Full Text] [Related]

  • 17. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
    Burrows GD, Maguire KP, Norman TR.
    J Clin Psychiatry; 1998 Aug; 59 Suppl 14():4-7. PubMed ID: 9818623
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.